NYSE · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Matinas BioPharma Holdings, Inc. MTNB
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
EPS · FY25
$-2.00
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-166.6%
Net margin · FY25
—
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
—
Revenue, FY2025 · full 13-year series below
Revenue
Net income
Per share
USD -2.00
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-166.6%
Return on equity, FY2025
ROE
Operating margin—
Net margin—
Return on assets-104.2%
Each USD of equity lost 167 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+55.7% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+90.6%
+55.7%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.01B
Shares outstanding, FY2025
Change, 5 years+132.7%
Change, 10 years—
The share count grew 133% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 7.2M
total assets, end of FY2025
Total assetsUSD 7.2M
EquityUSD 4.8M
CashUSD 4.0M
Current ratio2.79×
Equity funds 67% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
·
·
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
Operating income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EBITDA $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
Income tax $B
·
−0.0
·
·
·
·
·
0.0
0.0
·
·
0.0
·
Net income $B
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
EPS, diluted $
−2.00
−4.98
−5.28
−0.10
−0.11
−0.12
−0.13
−0.15
−0.36
−0.21
−0.18
−0.32
−0.20
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−166.6
−180.7
−82.1
−47.1
−40.1
−46.4
−70.6
−105.0
−173.7
−114.9
−220.1
−160.9
−35.4
Shares out B
0.01
0.01
0.00
0.22
0.00
0.00
0.00
0.11
0.09
0.06
0.06
0.03
0.03
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
39 of 39
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed